Drugs / Meta10-TIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meta10-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07307053 ↗ |
| Modality | Cell therapy | “tumor-infiltrating lymphocyte product” NCT07307053 ↗ |
| Route | Intravenous | “single intravenous infusion of Meta10-TIL” NCT07307053 ↗ |